During the last session, Bionano Genomics Inc (NASDAQ:BNGO)’s traded shares were 85261.0, with the beta value of the company hitting 2.13. The 52-week high for the BNGO share is $72.60, that puts it down -1692.59 from that peak though still a striking 33.83% gain since the share price plummeted to a 52-week low of $2.68. The company’s market capitalization is $12.18M, and the average intraday trading volume over the past 10 days was 0.34 million shares, and the average trade volume was 200.43K shares over the past three months.
Bionano Genomics Inc (BNGO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.33. BNGO has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Bionano Genomics Inc (NASDAQ:BNGO) trade information
The stock’s 5-day price performance is -7.95%, and it has moved by 22.73% in 30 days. Based on these gigs, the overall price performance for the year is -92.11%. The short interest in Bionano Genomics Inc (NASDAQ:BNGO) is 0.59 million shares and it means that shorts have 6.74 day(s) to cover.
The consensus price target of analysts on Wall Street is $2, which implies a decrease of -102.5% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1 and $175 respectively. As a result, BNGO is trading at a discount of -4220.99% off the target high and 75.31% off the low.
Bionano Genomics Inc (BNGO) estimates and forecasts
In the rating firms’ projections, revenue will decrease -1.44% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 6.25M as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 7.01M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 8.77M and 7.77M respectively. In this case, analysts expect current quarter sales to shrink by -28.73% and then drop by -9.75% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 40.63%. While earnings are projected to return 90.60% in 2025.
BNGO Dividends
Bionano Genomics Inc is due to release its next quarterly earnings on 2025-Mar-30. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Bionano Genomics Inc (NASDAQ:BNGO)’s Major holders
Bionano Genomics Inc insiders own 0.07% of total outstanding shares while institutional holders control 9.30%, with the float percentage being 9.31%. ARMISTICE CAPITAL, LLC is the largest shareholder of the company, while 56.0 institutions own stock in it. As of 2024-06-30, the company held over 1.68 million shares (or 89.9539% of all shares), a total value of $1.14 million in shares.
The next largest institutional holding, with 0.61 million shares, is of BLACKROCK INC.’s that is approximately 32.5763% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $0.41 million.
Also, the Mutual Funds coming in first place with the largest holdings of Bionano Genomics Inc (BNGO) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 22.74 shares. This amounts to just over 0.76 percent of the company’s overall shares, with a $92101.0 market value. The same data shows that the other fund manager holds slightly less at 20.72, or about 0.69% of the stock, which is worth about $83911.0.
